Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Fapon Biopharma's FP008 Cancer Therapy IND Application | Contract Pharma

What are you searching for?

Sign in
Breaking News

FDA Approves Fapon Biopharma’s FP008 Cancer Therapy IND Application

FP008 is a novel fusion protein combining anti-PD-1 and IL-10M, designed to treat anti-PD-1 naïve or resistant patients with reduced toxicity.

The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for FP008, an immunocytokine designed to address the unmet need in patients with solid tumors refractory to anti-PD-1 therapy.

FP008 is a novel anti-PD-1×IL-10M fusion protein with a unique mechanism of action (MOA) and therapeutic potential for anti-PD-1 naïve or resistant patients. IL-10 monomer (IL-10M) engineering significantly reduces its hematologic toxicity, while the anti-PD-1 antibody enhances IL-10M activity by PD-1 targeted enrichment and cis-activation.

Fapon Biopharma’s FP008 effectively counteracts PD-1 antibody-mediated exhaustion of CD8(+) T cells, enhancing anti-tumor effects and offering a new treatment option for solid tumors.

“Global collaboration is central to our vision,” stated President Vincent Huo. “We invite partners to leverage our robust preclinical data and clinical-stage asset to jointly advance innovative products in tumor immunotherapy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics